ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Koo Discusses Focal Therapy for Prostate Cancer

Alec S. Koo, MD
Published: Tuesday, Nov 10, 2015



Alec S. Koo, MD, FACS, managing partner, Skyline Urology, board of directors, Large Urology Group Practice Association (LUGPA), discusses targeted focal therapy for localized prostate cancer.

Focal therapy is a new concept that destroys small tumors while leaving the prostate intact and sparing most of the surrounding healthy tissue. It is intended to reduce the morbidity of treatment.

The efficacy of these treatments need to be proven over time, Koo says, and data will show in a number of years if cancer was missed in the areas left untreated.
 


Alec S. Koo, MD, FACS, managing partner, Skyline Urology, board of directors, Large Urology Group Practice Association (LUGPA), discusses targeted focal therapy for localized prostate cancer.

Focal therapy is a new concept that destroys small tumors while leaving the prostate intact and sparing most of the surrounding healthy tissue. It is intended to reduce the morbidity of treatment.

The efficacy of these treatments need to be proven over time, Koo says, and data will show in a number of years if cancer was missed in the areas left untreated.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x